These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17336894)

  • 1. Medical management of atrial fibrillation: future directions.
    Page RL
    Heart Rhythm; 2007 Mar; 4(3 Suppl):S91-4. PubMed ID: 17336894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel K+ Channel Targets in Atrial Fibrillation Drug Development--Where Are We?
    El-Haou S; Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):412-31. PubMed ID: 25978691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative Therapeutics for Atrial Fibrillation: Imminent Breakthroughs or Much Ado About Nothing?
    Nattel S; Dobrev D
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):409-11. PubMed ID: 26371951
    [No Abstract]   [Full Text] [Related]  

  • 4. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.
    Aguilar M; Nattel S
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):432-40. PubMed ID: 25923324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms.
    Hanley CM; Robinson VM; Kowey PR
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e002479. PubMed ID: 26936819
    [No Abstract]   [Full Text] [Related]  

  • 6. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
    Blaauw Y; Gögelein H; Tieleman RG; van Hunnik A; Schotten U; Allessie MA
    Circulation; 2004 Sep; 110(13):1717-24. PubMed ID: 15364815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atrial remodeling and anti-remodeling therapy in atrial fibrillation].
    Neumann T; Hölschermann H
    Dtsch Med Wochenschr; 2006 Apr; 131(16):884-7. PubMed ID: 16625482
    [No Abstract]   [Full Text] [Related]  

  • 13. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-channel drugs to prevent atrial fibrillation].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New directions in antiarrhythmic drug therapy for atrial fibrillation.
    Heijman J; Voigt N; Dobrev D
    Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-arrhythmic drugs for atrial fibrillation management.
    Ehrlich JR; Nattel S; Hohnloser SH
    Curr Vasc Pharmacol; 2007 Jul; 5(3):185-95. PubMed ID: 17627562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy.
    Diness JG; Bentzen BH; Sørensen US; Grunnet M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):441-8. PubMed ID: 25830485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
    Anderson ME
    J Cardiovasc Electrophysiol; 2006 Jun; 17(6):655-6. PubMed ID: 16836717
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.